Table 2.
Baseline demographic, phenotypic characteristics of MS patients (N = 467) on disease-modifying therapy
| Characteristic | B-cell depleters (N = 152) | Immune cell traffickers (N = 245) | Other (N = 70) |
|---|---|---|---|
| Age | 36 (27, 45) | 35 (29, 42) | 43 (34, 53) |
| Female gender, n (%) | 93 (61.2) | 143 (58.4) | 40 (57.1) |
| Arab ethnicity, n (%) | 118 (76.3) | 195 (79.6) | 59 (84.3) |
| RRMS phenotype, n (%) | 46 (30.3) | 237 (96.7) | 69 (98.6) |
| Duration of MS, years | 3 (1, 10) | 8 (5, 12) | 11 (6, 14) |
| Duration of current DMT, years | 2 (1, 3) | 5 (1.5, 7) | 3 (2, 5) |
Median (IQR) or N (%) is reported.